Full Press Release Details
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS.
IONS
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
Key Takeaway: Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS